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ABSTRACT
Objective Maternal alloimmunization to fetal red-
blood-cell antigens is a major cause of fetal anemia, which
can lead to hydrops and perinatal death if untreated. The
cornerstone of management during pregnancy is intrauter-
ine intravascular blood transfusion (IUT). Although this
procedure is considered relatively safe, complications con-
tinue to occur. The aim of this study was to evaluate rates
of procedure-related complications and perinatal loss fol-
lowing IUT, and their change over time, in order to
identify factors leading to improved outcome.
Methods This was a retrospective analysis of all IUTs
for red-cell alloimmunization performed at the national
referral center for fetal therapy in The Netherlands, from
1988 to 2015. Differences in complication rates and their
associations with alterations in transfusion technique after
2001 were assessed.
Results Between 1988 and 2015, 1678 IUTs were
performed in 589 fetuses. For IUTs performed in 2001
and onwards, there was significant improvement in
survival (88.6% vs 97.0%, P < 0.001) and a decline
in procedure-related complications per fetus (9.8% vs
3.3%, P = 0.001) and per procedure (3.4% vs 1.2%,
P = 0.003) compared with those performed before 2001.
Procedure-related perinatal loss declined from 4.7%
to 1.8% per fetus (P = 0.053). Beneficial changes in
transfusion technique were routine use of fetal paralysis,
increased use of intrahepatic transfusion and avoidance
of arterial puncture.
Conclusions IUT has become an increasingly safe
procedure in recent years when performed by experienced
hands. The chosen technique should be fine-tuned
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according to the patient’s individual situation. The
declining complication rates are most likely related to
center volume: this rare procedure is best performed in
experienced fetal therapy centers. © 2016 The Authors.
Ultrasound in Obstetrics & Gynecology published by
John Wiley & Sons Ltd on behalf of the International
Society of Ultrasound in Obstetrics and Gynecology.
INTRODUCTION
Since its introduction in 1981, intrauterine intravascular
blood transfusion (IUT) has become the cornerstone of
treatment for fetal anemia in pregnancies complicated
by red-cell alloimmunization1. In experienced hands, it
is nowadays considered a safe procedure, significantly
improving perinatal outcome in fetuses with severe
anemia2,3.
One way to improve fetal outcome further is to
minimize the occurrence of procedure-related (PR)
complications associated with IUT. A PR fetal-loss rate
of approximately 2% per procedure was reported in
a review by Schumacher and Moise4. However, the
small studies included in their review used a variety of
definitions for complications and treatment techniques.
In 2005, we reported PR complications and fetal-loss
rates of 3.1% and 1.6% per procedure, respectively,
in a single-center series of 740 IUTs5. In our study,
transamniotic ‘free loop’ needling, inadvertent arterial
puncture and refraining from the use of fetal paralysis
were identified as risk factors for adverse outcome5.
Apart from the technical aspects, operator and team
experience are known to be of utmost importance for
performing successful and safe IUTs 6. In recent years, a
few smaller studies have been performed on this subject,
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revealing no relevant new insights or tools to improve
perinatal outcome further after IUT7,8.
The present study aimed to evaluate PR complications
and perinatal loss rates after IUT, including assessment
of their change over time, over a period of nearly three
decades in a national single-center cohort, in order to
identify factors leading to improved outcome.
METHODS
Patients
We included all patients treated with IUT between January
1988 and January 2015 at the national referral center for
fetal therapy in Leiden, The Netherlands, for fetal anemia
caused by red-blood-cell alloimmunization. The findings
of IUTs performed between 1988 and 2001 have been
analyzed and published previously5.
Patient data, technical aspects of IUT and complications
were collected from our custom-built electronic Rhesus
database. As early IUT is known to be associated with
higher perinatal loss rates9–12, we compared outcomes
after IUTs performed before and after 20 weeks’ gestation
to determine whether expected improvements in survival
also apply to very young anemic fetuses. To identify
changes in procedural techniques and perinatal outcome,
pregnancies were divided into two cohorts according to
year of procedure. The first cohort included patients with
a first IUT before January 2001, described previously5,
and the second cohort included patients with a first IUT
performed from 1 January 2001 onwards. This policy was
chosen as it was assumed that the findings of our first study
in 20055 may have resulted in gradual changes in trans-
fusion techniques and therefore also in perinatal survival.
Complications after IUT were classified independently
into PR or non-procedure related (NPR)5 by two
operators (I.L.v.K. and D.O.). In summary, fetal condition
before IUT was assessed by ultrasound (presence of
hydrops, biophysical profile), fetal heart rate tracing
in fetuses > 26 weeks’ gestation and blood gas analysis
of the fetal blood sample obtained before transfusion
(a blood pH of ≤ 7.25 was considered a sign of fetal
compromise)5. If a complication occurred during or after
a complicated procedure in a fetus with a reasonable
condition prior to IUT based on the abovementioned
findings, the complication was considered to be related to
the procedure i.e. PR. In fetuses with an unfavorable
condition prior to an uncomplicated procedure, the
complication was classified as not related to the procedure
i.e. NPR. If the experts could not agree on classification,
the complication remained unclassified.
The following complications were taken into account:
rupture of membranes or preterm delivery within 7 days
after IUT, if occurring before 34 weeks of gestation; and
intrauterine infection and fetal distress resulting in either
emergency Cesarean section (CS) within 24 h after IUT or
fetal or neonatal death.
Primary outcomes assessed were perinatal survival and
PR complications. Furthermore, we assessed primary
antibody type, gestational age at first IUT, fetal
hemoglobin concentration and presence of hydrops at
first IUT, procedure access site and other technical details
of IUT, number of transfusions per fetus and gestational
age at delivery.
Diagnostics
Patients with red-cell alloimmunization were referred,
according to national guidelines, to our center in Leiden,
The Netherlands, which has served as the national
referral center for fetal therapy since 1965. Indication
for referral is based on type and titer of antibody, level
of antibody-dependent cell-mediated cytotoxicity assay13
and obstetric history.
In the first decade of the study period, amniotic fluid
delta optical density measurements at 450 nm were used
to assess the likelihood of fetal anemia. In later years,
the peak systolic velocity in the fetal middle cerebral
artery (MCA-PSV) was used to determine the optimal
timing of first and subsequent IUTs14–16. Cordocentesis
was performed if MCA-PSV exceeded 1.5 multiples of
the median and/or if signs of hydrops were detected on
ultrasound, and was followed by transfusion if the fetal
blood sample showed fetal anemia.
Intrauterine intravascular blood transfusion technique
Our IUT technique has been described comprehensively in
a previous publication3. No routine antibiotic prophylaxis
or corticosteroid was administered prior to IUT. In nearly
all recent cases, atracurium was given intravenously (or
intramuscularly) to the fetus prior to transfusion to cause
fetal paralysis.
IUT was carried out under aseptic conditions, using a
20- or 22-G needle. In this study, all IUT attempts were
made intravascularly. As a result of our prior study5, fetal
paralysis was applied more often and known risk factors
for PR complications, such as transamniotic needling (also
known as ‘free loop’ needling) and arterial puncture,
were avoided more consciously in the second half of
the study. A tailored mode of transfusion was chosen
depending on the fetal anatomy, preferably transfusing
into the placental cord insertion in the case of an anterior
placenta and into the fetal intrahepatic umbilical vein in
the case of a posterior placenta, often in combination
with additional intraperitoneal transfusion. For both time
cohorts, a maximum of four experienced operators were
involved, all capable of applying different transfusion
techniques. IUT was considered to be successful if more
blood than was acquired for fetal blood sampling was
transfused to the fetus, as verified by ultrasound.
Fetal condition was monitored before, during and after
transfusion. If the condition of the mother and fetus was
satisfactory, patients were discharged within 6 h after IUT.
Statistical analysis
To compare proportions, Fisher’s exact test (or Pearson’s
chi-square test, when appropriate), binary logistic
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Table 1 Characteristics of 1678 intrauterine intravascular blood transfusions (IUTs) in 589 fetuses with anemia caused by red-cell
alloimmunization, according to study period in which procedure was performed
Characteristic
1988–2000
(n = 255 fetuses/741 IUTs)
2001–2015
(n = 334 fetuses/937 IUTs) P
Primary immunization against:
Rhesus D 217 (85.1) 255 (76.3) 0.009
Kell 25 (9.8) 53 (15.9) 0.037
Other* 13 (5.1) 26 (7.8) 0.242
GA at first IUT (weeks) 27 (17 to 36) 27 (16 to 35) 0.787
Hydrops at first IUT 97 (38.0) 43 (12.9) < 0.001
Hemoglobin at first IUT (g/dL) 4.8 (1.1 to 13.2) 6.3 (1.5 to 12.9) < 0.001
Z-hemoglobin at first IUT† −8.3 (−12.2 to −0.24) −6.9 (−11.7 to −0.5) <0.001
 Hemoglobin (after IUT − before IUT) (g/dL) 4.5 (−0.5 to 11.2) 4.4 (0.5 to 9.2) 0.039
Number of IUTs per fetus 3 (1 to 7) 3 (1 to 6) 0.337
GA at delivery of liveborn (weeks) 37 (30 to 39) 36 (28 to 39) < 0.001
Data are given as n (%) or median (range). *Rhesus c, E or e, Duffy (Fya), Kidd (Jka), rare or low-frequency antigens. †Number of SDs from
median concentration for gestational age. GA, gestational age.
regression (Wald test) or Mann–Whitney U-test was used.
The independent t-test was used for comparison of means.
All variables with P-value of ≤ 0.15 in univariate analysis
were included in a multiple logistic regression model to
identify possible independent risk factors for severe PR
complications (emergency CS or death). A P-value of
< 0.05 was considered statistically significant.
RESULTS
During the 27-year study period, 595 fetuses in 587
pregnancies of 497 women received a total of 1685 IUTs,
of which 740 were described previously5. In eight twin
pregnancies, both twins had anemia as a result of red-cell
immunization and received IUTs. In one additional twin
pregnancy, one fetus was affected and was included in
this study; the cotwin was Rhesus D (RhD) negative.
Six singleton pregnancies, in which fetal death occurred
from causes unrelated to red-cell alloimmunization, were
excluded, as described in detail previously5. Therefore,
589 fetuses were treated with a total of 1678 IUTs in 581
pregnancies of 491 women. Of these, 741 procedures were
performed in 255 fetuses before 2001 and 937 procedures
were performed in 334 fetuses from 2001 onwards.
Overall perinatal survival was 93.4%, significantly
increasing from 88.6% in the first time-cohort to
97.0% in the second time-cohort (odds ratio (OR), 4.2
(95% CI, 2.0–8.7), P < 0.001). Characteristics of the
study population in both time-cohorts are summarized
in Table 1. The main type of immunization was for
RhD, although this significantly decreased from 85.1%
before 2001 to 76.3% from 2001 onwards (P = 0.009),
whereas the proportion of Kell immunization increased
(9.8% to 15.9%, P = 0.037, Table 1). In the second
time-cohort, four patients were treated with intravenous
immunoglobulin prior to the first transfusion.
Complications
In a total of 1678 IUTs, 69 complications occurred.
Forty-four of these were considered as being directly
related to the procedure (PR). In eight patients, one PR
complication led to another (five emergency CSs followed
by perinatal death, two intrauterine infections followed by
perinatal death and one intrauterine infection followed by
emergency CS). After correction for this, the actual PR
complication rates for the total cohort over 27 years were
6.1% per fetus and 2.1% per procedure. Survival and PR
complications are listed in Table 2.
In the first time-cohort, there were 51 complications
(seven women each had two complications; actual com-
plication rate = 5.9% per procedure) and in the second
time-cohort there were 18 (one women had two compli-
cations; actual complication rate = 1.7% per procedure)
(P < 0.001). Compared with the first cohort, the incidence
of PR complications significantly declined in the second
cohort, from 9.8% to 3.3% per fetus (OR, 0.3 (95% CI,
0.2–0.7), P = 0.001) and from 3.4% to 1.2% per proce-
dure (OR, 0.3 (95% CI, 0.2–0.7), P = 0.003). The risk of
PR perinatal loss decreased over time from 4.7% to 1.8%
per fetus and from 1.6% to 0.6% per procedure (Table 2).
Preterm prelabor rupture of membranes and preterm
delivery
In three cases, preterm prelabor rupture of membranes
(PPROM) occurred within 7 days after transfusion,
leading to preterm delivery before 34 weeks. One PR
and one NPR classified PPROM are described in more
detail in our previously published cohort study5. In the
second time-cohort, PPROM occurred in one case, the
day after the first IUT at 30 weeks’ gestation. The baby
was liveborn 8 days later. As it took three attempts to
complete the transfusion successfully, this complication
was classified as PR. The PR-PPROM rate was thus low
in both cohorts and did not differ significantly (Table 2).
Infection
Three cases of culture-proven intrauterine infection
with Escherichia coli were observed, and all three were
classified as PR. Two cases were part of our previously
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Table 2 Outcome and procedure-related complications after 1678 intrauterine intravascular blood transfusions (IUTs) in 589 fetuses with
anemia caused by red-cell alloimmunization, according to study period in which procedure was performed
Outcome
1988–2000
(n = 255 fetuses/
741 IUTs)
2001–2015
(n = 334 fetuses/
937 IUTs) OR (95% CI) P
Survival (n (%))* 226 (88.6) 324 (97.0) 4.16 (2.0–8.7) < 0.001
Procedure-related complication (n) 32 12
Per fetus (n (%))† 25 (9.8) 11 (3.3) 0.31 (0.2–0.7) 0.001
Per procedure (n (%))† 25 (3.4) 11 (1.2) 0.34 (0.2–0.7) 0.003
Procedure-related PPROM (n) 1 1
Per fetus (%) 0.4 0.3 0.76 (0.0–12.3) 1.000
Per procedure (%) 0.1 0.1 0.79 (0.0–12.7) 1.000
Procedure-related infection (n) 2 1
Per fetus (%) 0.8 0.3 0.38 (0.0–4.2) 0.581
Per procedure (%) 0.3 0.1 0.40 (0.0–4.4) 0.587
Procedure-related emergency CS (n) 17 4
Per fetus (%) 6.7 1.2 0.17 (0.1–0.5) < 0.001
Per procedure (%) 2.3 0.4 0.18 (0.1–0.5) < 0.001
Procedure-related loss (n) 12 6
Per fetus (%) 4.7 1.8 0.37 (0.1–1.0) 0.053
Per procedure (%) 1.6 0.6 0.39 (0.1–1.0) 0.059
*Alive at discharge from tertiary center. †Actual number and rate (eight patients had two interrelated complications). CS, Cesarean section;
OR, odds ratio; PPROM, preterm prelabor rupture of membranes.
published cohort with IUTs before 20015. A third case
occurred in the second cohort after IUT at 18 weeks. The
infection led to fetal loss and was considered to be PR.
The decrease in PR infections over time, from 0.8% to
0.3% per fetus and from 0.3% to 0.1% per procedure,
was not significant (Table 2).
Emergency Cesarean section
Within 24 h after IUT, 24 fetuses were delivered by
emergency CS for fetal distress, which was considered
PR in 21 cases. Five children died subsequently; all deaths
were PR and have been described previously5. As fetal
condition in two of the six cases in the second cohort
was unfavorable prior to an uncomplicated IUT, these
complications were considered NPR. One case of PR
intrauterine infection resulted in emergency CS5. In one
case, emergency CS was performed at 34 weeks’ gestation
for persistent tachycardia after transfusion, probably
triggered by volume overload, and was considered as PR.
The three remaining cases of CS at 32, 34 and 35 weeks
were all classified as PR. All neonates in the second cohort
survived after emergency CS. In summary, the occurrence
of PR emergency CS decreased from 6.7% in the first
cohort to 1.2% in the second cohort (P < 0.001) and
from 2.3% to 0.4% per procedure (P < 0.001).
Fetal or neonatal death
During the study period, a total of 39 cases of fetal
or neonatal death occurred after IUT, of which 10
occurred from 2001 onwards. In this second cohort,
one patient with RhD immunization was treated initially
with (a possibly incomplete) interstitial laser for twin
reversed arterial perfusion syndrome and fetal death
was detected the day after the third uncomplicated IUT.
Because of the complexity of this case, this complication
could not be clearly classified as PR or NPR. Three of
the nine remaining cases of loss were considered to be
NPR. One NPR loss occurred after the decision to stop
intrauterine treatment, as a result of refractory severe
hydrops that was diagnosed relatively late and was caused
by antibodies against a low-frequency antigen. In the two
other cases, fetal death was detected 19 and 22 days after
an uncomplicated IUT and, because of the time lapse
between the procedure and the death, these deaths were
considered as being NPR.
Therefore, a total of six PR losses occurred in the
second cohort, including one with E. coli infection that
was described earlier. In three patients, multiple attempts
at intravenous access led to bradycardia during the
procedure, leading to fetal loss directly, and at 1 and
8 days later. Two other PR fetal losses occurred within
1 week after IUTs at 16 and 26 weeks in fetuses with a
reasonable condition prior to IUT. We thus saw a decrease
in PR death rates from 4.7% to 1.8% per fetus (P = 0.053)
and from 1.6% to 0.6% per procedure (P = 0.059).
Fetal death occurred after eight (17.0%) of 47 IUTs
performed before 20 weeks. Four of these were classified
as NPR and four as PR, one of the latter was preceded by
infection. Fetal demise in the total cohort occurred more
often before 20 weeks than after 20 weeks, accounting for
both NPR (8.5% vs 1.0% per procedure; P = 0.002)
and PR (8.5% vs 0.9%; P = 0.001) fetal death. No
significant difference was found in PR fetal-loss rate before
20 weeks between the first and the second time-cohort
(P = 0.083).
Technical details
In the second time-cohort, significantly more procedures
were completed successfully than in the first time-cohort
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(96.8% vs 99.0%, P = 0.001). The number of attempts
per procedure decreased (median, 1 (range, 1–7) vs 1
(range, 1–5), P < 0.001). From 2001 onward, the fetal
liver was the most frequently chosen procedure access site
(48.0% in the second cohort vs 13.8% in the first cohort,
P < 0.001). Trends in procedure access sites over time are
presented in Figure 1.
Fetal paralysis was applied significantly more frequently
(97.8% vs 81.3%, P < 0.001) and transamniotic needling
in a free loop of cord was performed less frequently (3.7%
vs 33.1%, P < 0.001) from 2001 onwards compared with
before 2001. No arterial punctures were performed after
2001 (0.0% vs 3.2%, P < 0.001).
In Table 3, procedures that were followed by severe
PR complications (fetal distress resulting in emergency CS
or death) are compared with the remaining procedures
by univariate analysis. Hydrops was not associated











































Figure 1 Trends in procedure access sites for intrauterine
intravascular blood transfusion between January 1988 and January
2015. , liver (plus intraperitoneal); , placental cord
insertion; , transamniotic venous; , arterial (cord insertion
or transamniotic); , intraperitoneal; , unknown vessel,
heart, chorionic vein.
(number of SDs from median concentration for gestational
age), fetal paralysis, procedure access site and unsuccessful
IUT were included in a multiple regression model.
A positive association with severe PR complications
was found for transamniotic (P = 0.030) and arterial
(P < 0.001) transfusion sites, compared with transfusion
into the fetal liver. There was a negative association
of PR complications with fetal paralysis (P = 0.034).
Intrahepatic and placental cord insertion sites were
equally safe (P = 0.597).
DISCUSSION
In this cohort of 589 fetuses treated with 1678 IUTs for
fetal anemia caused by red-cell immunization, we found
an improvement in perinatal survival over time, from
88.6% in 1988–2000 to 97.0% from 2001 onwards.
The incidence of PR complications decreased significantly
in the last decade. PR loss rates declined from 4.7% to
1.8% per fetus and from 1.6% to 0.6% per procedure,
a decrease that approached statistical significance. In
spite of our policy not to apply routine antibiotics
prior to transfusion, PR infection rate was extremely
low (0.1% per procedure). These results suggest that
intrauterine treatment for red-cell immunization has
become significantly safer in the past decade.
Recently, three other European fetal therapy centers
reported on PR complications and loss rates7,8,17. Pasman
et al. found a comparable PR complication rate (1.5%)
in 135 procedures performed between 2000 and 2014,
although no perinatal death occurred in the 56 fetuses
in their study8. We found lower overall PR perinatal
loss rates compared with another recent European study,
by Tiblad et al., in which four of 85 fetuses died as
a direct result of the procedure (4.7% per fetus, 1.4%
per procedure) performed between 1990 and 20107, and
with the third study by Sainio et al., which had a 3.8% PR
fetal-loss rate17. None of these studies compared trends
in results over time.
Table 3 Univariate analysis of characteristics of 34 intrauterine intravascular blood transfusions (IUTs) that were followed by severe
procedure-related (PR) complications, compared with 1644 remaining procedures in 589 fetuses with anemia caused by red-cell
alloimmunization
Characteristic
IUT with PR complication*
(n = 34)
Remaining IUTs
(n = 1644) OR (95% CI) P
Hydrops at IUT 7 (20.6) 231 (14.1) 1.6 (0.7–3.7) 0.315
GA at IUT (weeks) 31.1 (16.0 to 35.1) 29.9 (16.4 to 37.0) — 0.411
Z-hemoglobin at IUT† −7.4 (−12.2 to −3.6) −6.8 (−11.7 to 1.4) 0.8 (0.7–1.0) 0.016
Fetal paralysis 23 (67.6) 1440 (87.6) 0.2 (0.1–0.5) 0.001
Procedure access site
Liver 6 (17.6) 546 (33.2) 0.4 (0.2–1.0) 0.065
Placental cord insertion 11 (32.4) 787 (47.9) 0.5 (0.3–1.1) 0.083
Transamniotic ‘free loop’ 10 (29.4) 270 (16.4) 2.1 (1.0–4.5) 0.060
Artery 4 (11.8) 20 (1.2) 10.8 (3.5–33.6) 0.001
Intraperitoneal 0 (0) 13 (0.8) — 1.000
Other‡ 3 (8.8) 8 (0.5) 19.8 (5.0–78.2) 0.001
Unsuccessful IUT 3 (8.8) 30 (1.8) 5.2 (1.5–18.0) 0.027
Data are given as n (%) or median (range). *Procedures followed by fetal distress resulting in emergency Cesarean section within 24 h or
fetal death. †Number of SDs from median concentration for gestational age (GA). ‡Unknown vessel, heart, chorionic vein. OR, odds ratio.
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The increase in survival in our study may be explained,
in part, by reduced severity of the disease at referral
in the second cohort, reflected by a lower hydrops
rate and higher hemoglobin concentrations at first
IUT18,19. This improvement reflects the optimization
of the Dutch program for detection and prevention of
red-cell antibodies20,21. We showed previously that fetal
hydrops was associated with adverse outcome, both
short- and long-term18,19, but not with occurrence of
PR complications5, as confirmed in the present study.
The decline in number of RhD immunizations during
the study period is probably best explained by the
introduction of routine prophylactic administration of
anti-D in the 30th week of gestation in 199822, in addition
to postnatal anti-D.
It is likely that the most important factor associated
with our low complication rates is the large number of
IUTs performed annually at our center (mean, 62 per
year vs 10, 14 and 38 per year in Tiblad et al.7, Pasman
et al.8 and Sainio et al.17, respectively), which enhances
operator and team experience and thus also diminishes
PR complication rates6.
We hypothesize that the extensive decline in PR
complications is the result of avoiding possibly hazardous
techniques in the more recent procedures. Risk factors
for adverse outcome were identified previously5 and were
confirmed in the current study as being arterial puncture,
transamniotic ‘free loop’ needling and refraining from
fetal paralysis. These technical aspects occurred signifi-
cantly less frequently in procedures performed from 2001
onwards in our study, compared with procedures carried
out before this timepoint. Furthermore, the fetal liver
gained impressive popularity as a procedure access site,
as this is associated with very low complication and loss
rates and is considered to be a safe route of access5,23,24.
In the previously mentioned studies with higher reported
complication rates, 15.5%7 and 63.8%17 of transfusions
were transamniotic.
Our current study shows that early IUT is still a
hazardous procedure, as both NPR and PR complications
occur more often before 20 weeks. Early IUT is technically
more challenging, resulting in a higher complication risk.
Unfortunately, evidence-based studies on the benefit of
intravenous immunoglobulin treatment to postpone the
first IUT are still lacking. We are currently evaluating the
effect of intravenous immunoglobulin in an international
multicenter cohort study.
One of the strengths of our study is that all com-
plications were independently and thoroughly classified
as PR or NPR. Furthermore, the size of our cohort is
considerably larger than those in other published studies.
The retrospective design of this study carries some limi-
tations. For example, the rationale for decisions on techni-
cal details of procedures by individual operators is difficult
to determine retrospectively. However, because of the
available evidence supporting transfusion techniques, ran-
domization into different strategies to identify risk factors
prospectively could be considered as unethical5,8. Another
limitation of this study could be that we did not address
neonatal outcomes other than death. This was a deliber-
ate choice, as our focus was on severe PR complications.
Furthermore, short- and long-term outcomes of IUTs have
recently been thoroughly addressed by our group19.
Our study demonstrates that IUTs should be a
tailored treatment, with the chosen technique fine-tuned
to the patient’s situation. We advocate that every
operator should master all transfusion techniques and
maintain experience by performing a sufficient number of
transfusions per year in an experienced team. A minimum
number of 10 transfusions annually for experienced
operators has been suggested6. In order to achieve this
target, centralization of fetal therapy is necessary.
In summary, we found that IUT for red-cell immuniza-
tion has become a safer treatment option for fetal anemia.
We believe that our current PR fetal-loss rates (1.8% per
fetus and 0.6% per procedure) can be considered ‘as good
as it gets’ in experienced hands. For the future, we are
focusing our research on non-invasive treatment, such as
immunomodulation with intravenous immunoglobulin.
ACKNOWLEDGMENTS
We thank Annemieke Middeldorp and Monique Haak,
Department of Obstetrics at Leiden University Medical
Center, for their important contribution to our IUT team,
Robertjan Meerman and Jenny Verdoes, Department of
Obstetrics at Leiden University Medical Center, for their
invaluable help retrieving the data and Ron Wolterbeek,
Department of Medical Statistics and Bioinformatics at
Leiden University, for his assistance with analyzing the
data. This research was partly funded by a grant from
Sanquin, Amsterdam, which did not influence design,
conduct or publication of the study.
REFERENCES
1. Rodeck CH, Kemp JR, Holman CA, Whitmore DN, Karnicki J, Austin MA. Direct
intravascular fetal blood transfusion by fetoscopy in severe Rhesus isoimmunisation.
Lancet 1981; 1: 625–627.
2. Kanhai HH, Bennebroek Gravenhorst J, van Kamp IL, Meerman RH, Brand
A, Dohmen-Feld MW, Ruys JH. Management of severe hemolytic disease with
ultrasound-guided intravascular fetal transfusions. Vox Sang 1990; 59: 180–184.
3. van Kamp IL, Klumper FJ, Meerman RH, Oepkes D, Scherjon SA, Kanhai HH.
Treatment of fetal anemia due to red-cell alloimmunization with intrauterine
transfusions in the Netherlands, 1988–1999. Acta Obstet Gynecol Scand 2004;
83: 731–737.
4. Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in
pregnancy. Obstet Gynecol 1996; 88: 137–150.
5. Van Kamp IL, Klumper FJ, Oepkes D, Meerman RH, Scherjon SA, Vandenbussche
FP, Kanhai HH. Complications of intrauterine intravascular transfusion for fetal
anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 2005; 192:
171–177.
6. Lindenburg IT, Wolterbeek R, Oepkes D, Klumper FJ, Vandenbussche FP, van Kamp
IL. Quality control for intravascular intrauterine transfusion using cumulative sum
(CUSUM) analysis for the monitoring of individual performance. Fetal Diagn Ther
2011; 29: 307–314.
7. Tiblad E, Kublickas M, Ajne G, Bui TH, Ek S, Karlsson A, Wikman A, Westgren
M. Procedure-related complications and perinatal outcome after intrauterine
transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther 2011;
30: 266–273.
8. Pasman SA, Claes L, Lewi L, Van Schoubroeck D, Debeer A, Emonds M, Geuten E,
De Catte L, Devlieger R. Intrauterine transfusion for fetal anemia due to red blood
cell alloimmunization: 14 years experience in Leuven. Facts Views Vis Obgyn 2015;
7: 129–136.
9. Yinon Y, Visser J, Kelly EN, Windrim R, Amsalem H, Seaward PG, Ryan G. Early
intrauterine transfusion in severe red blood cell alloimmunization. Ultrasound Obstet
Gynecol 2010; 36: 601–606.
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; 50: 180–186.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
186 Zwiers et al.
10. Canlorbe G, Mace G, Cortey A, Cynober E, Castaigne V, Larsen M, Mailloux
A, Carbonne B. Management of very early fetal anemia resulting from red-cell
alloimmunization before 20 weeks of gestation. Obstet Gynecol 2011; 118:
1323–1329.
11. Poissonnier MH, Picone O, Brossard Y, Lepercq J. Intravenous fetal exchange
transfusion before 22 weeks of gestation in early and severe red-cell fetomaternal
alloimmunization. Fetal Diagn Ther 2003; 18: 467–471.
12. Lindenburg IT, van Kamp IL, van Zwet EW, Middeldorp JM, Klumper FJ, Oepkes
D. Increased perinatal loss after intrauterine transfusion for alloimmune anaemia
before 20 weeks of gestation. BJOG 2013; 120: 847–852.
13. Oepkes D, van Kamp IL, Simon MJ, Mesman J, Overbeeke MA, Kanhai HH. Clinical
value of an antibody-dependent cell-mediated cytotoxicity assay in the management
of Rh D alloimmunization. Am J Obstet Gynecol 2001; 184: 1015–1020.
14. Mari G, Deter RL, Carpenter RL, Rahman F, Zimmerman R, Moise KJ, Jr.,
Dorman KF, Ludomirsky A, Gonzalez R, Gomez R, Oz U, Detti L, Copel JA,
Bahado-Singh R, Berry S, Martinez-Poyer J, Blackwell SC. Noninvasive diagnosis by
Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization.
Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic
Fetuses. N Engl J Med 2000; 342: 9–14.
15. Oepkes D, Seaward PG, Vandenbussche FP, Windrim R, Kingdom J, Beyene J, Kanhai
HH, Ohlsson A, Ryan G; DIAMOND Study Group. Doppler ultrasonography versus
aminiocentesis to predict fetal anemia. N Engl J Med 2006; 355: 156–164.
16. Mari G, Norton ME, Stone J, Berghella V, Sciscione AC, Tate D, Schenone MH.
Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: The fetus at risk
for anemia-diagnosis and management. Am J Obstet Gynecol 2015; 212: 697–710.
17. Sainio S, Nupponen I, Kuosmanen M, Aitokallio-Tallberg A, Ekholm E, Halmesmaki
E, Orden MR, Palo P, Raudaskoski T, Tekay A, Tuimala J, Uotila J, Stefanovic V.
Diagnosis and treatment of severe hemolytic disease of the fetus and newborn:
a 10-year nationwide retrospective study. Acta Obstet Gynecol Scand 2015; 94:
383–390.
18. van Kamp IL, Klumper FJ, Bakkum RS, Oepkes D, Meerman RH, Scherjon SA,
Kanhai HH. The severity of immune fetal hydrops is predictive of fetal outcome after
intrauterine treatment. Am J Obstet Gynecol 2001; 185: 668–673.
19. Lindenburg IT, van Klink JM, Smits-Wintjens VE, van Kamp IL, Oepkes D,
Lopriore E. Long-term neurodevelopmental and cardiovascular outcome after
intrauterine transfusions for fetal anaemia: a review. Prenat Diagn 2013; 33:
815–822.
20. de Haas M, Thurik FF, Koelewijn JM, van der Schoot CE. Haemolytic disease of the
fetus and newborn. Vox Sang 2015; 109: 99–113.
21. Koelewijn JM, Vrijkotte TG, van der Schoot CE, Bonsel GJ, de Haas M. Effect of
screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the
fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48:
941–952.
22. Koelewijn JM, de Haas M, Vrijkotte TG, Bonsel GJ, van der Schoot CE. One single
dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and
hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008;
48: 1721–1729.
23. Nicolini U, Nicolaidis P, Fisk NM, Tannirandorn Y, Rodeck CH. Fetal blood
sampling from the intrahepatic vein: analysis of safety and clinical experience with
214 procedures. Obstet Gynecol 1990; 76: 47–53.
24. Somerset DA, Moore A, Whittle MJ, Martin W, Kilby MD. An audit of
outcome in intravascular transfusions using the intrahepatic portion of the
fetal umbilical vein compared to cordocentesis. Fetal Diagn Ther 2006; 21:
272–276.
© 2016 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2017; 50: 180–186.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
